Biomarker-driven immunotherapy for precision medicine in prostate cancer.

IF 1.7 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Personalized medicine Pub Date : 2022-01-01 Epub Date: 2021-12-07 DOI:10.2217/pme-2021-0079
Arianna Ottini, Pierangela Sepe, Teresa Beninato, Mélanie Claps, Valentina Guadalupi, Elena Verzoni, Patrizia Giannatempo, Giulia Baciarello, Filippo de Braud, Giuseppe Procopio
{"title":"Biomarker-driven immunotherapy for precision medicine in prostate cancer.","authors":"Arianna Ottini,&nbsp;Pierangela Sepe,&nbsp;Teresa Beninato,&nbsp;Mélanie Claps,&nbsp;Valentina Guadalupi,&nbsp;Elena Verzoni,&nbsp;Patrizia Giannatempo,&nbsp;Giulia Baciarello,&nbsp;Filippo de Braud,&nbsp;Giuseppe Procopio","doi":"10.2217/pme-2021-0079","DOIUrl":null,"url":null,"abstract":"<p><p>Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient's individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (<i>POLE</i>), high tumor mutational burden and the presence of biallelic loss of <i>CDK12</i> among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 1","pages":"51-66"},"PeriodicalIF":1.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0079","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient's individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (POLE), high tumor mutational burden and the presence of biallelic loss of CDK12 among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.

生物标志物驱动免疫疗法在前列腺癌精准医学中的应用。
尽管免疫疗法最近已经彻底改变了不同癌症类型的护理标准,但前列腺癌通常未能对免疫检查点抑制剂表现出显著的反应。和其他肿瘤一样,现在治疗前列腺癌的目标是通过精准医学更精确地针对患者的个体特征进行治疗。错配修复缺陷、DNA聚合酶epsilon (POLE)外切酶结构域突变、高肿瘤突变负担和CDK12双等位基因缺失等都是对免疫治疗反应的预测性生物标志物。在本综述中,我们总结了前列腺癌免疫治疗的发展前景,包括精确的方法和策略,以确定反应性患者的类别,并扩大对免疫检查点抑制剂的耐药性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Personalized medicine
Personalized medicine 医学-药学
CiteScore
3.30
自引率
4.30%
发文量
49
审稿时长
6-12 weeks
期刊介绍: Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信